Crossref
Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies
JACC · 2026-08 · 88 (6) · 710-712
DOI: 10.1016/j.jacc.2026.06.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-08. Verfasst von John Erhabor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. E…. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
GLP-1 receptor agonistcardiovascular preventionimplementation
Autor:innen und Institutionen
- Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: john.erhabor@sgmc.org.
- Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zitieren
APA
Erhabor, J., Silver, N., & Blaha, M. J. (2026). Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies. JACC, 88(6), 710-712. https://doi.org/10.1016/j.jacc.2026.06.024
Vancouver
Erhabor J, Silver N, Blaha MJ. Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies. JACC. 2026;88(6):710-712. doi:10.1016/j.jacc.2026.06.024
BibTeX
@article{Erhabor2026,
author = {Erhabor, John and Silver, Nader and Blaha, Michael J},
title = {Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies},
journal = {JACC},
year = {2026},
volume = {88},
number = {6},
pages = {710--712},
doi = {10.1016/j.jacc.2026.06.024}
}
EUVIMED